bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. The company’s Molecular Fingerprint™ (mPrint™) platform creates a comprehensive, multi-omic and spatial profile of tissue to get a complete and informed understanding of the patient’s cancer so they can be matched with relevant therapies and recommended course of actions that prevent acquired drug resistance. bioSyntagma’s mPrint™ platform serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.